The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the ...

In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was “taking these difficult but necessary ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...

In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...

Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.

In the recent Fiscal Year 2025 Second Quarter Earnings Call, 23andMe Holding Co. (NASDAQ: ME) CEO Anne Wojcicki detailed significant restructuring plans, including a 40% reduction in workforce and ...

23andMe, the struggling ancestry tracing company ... could happen to its sensitive customer genetic testing data. CEO Anne Wojcicki has said she intends to take the company private and is not ...

Me is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest ...

23andMe announced on Monday it would cut 40 ... business and research partnerships,” said CEO and co-founder Anne Wojcicki in a press release. “I want to thank our team for their hard work ...